The approval is supported by data from the Phase III NRG-GY018/ KEYNOTE-868 trial, in which the regimen reduced the risk of disease progression or death by 40% in patients whose cancer was mismatch repair proficient and by 70% in patients whose cancer was mismatch repair deficient, when compared to placebo with carboplatin and paclitaxel followed by placebo alone
Do not wait for routine labs Severe headaches, vision changes, fainting, chest pain, rapid swelling, or neurologic symptoms need medical review
These agencies had no further role in the study design, collection, analysis or interpretation of the data, the writing of the report, or in the decision to submit the paper for publication
10.1023/A:1025497806636 [DOI] [PubMed] [Google Scholar] Khavinson VK, Solovyov AY, Shataeva LK (2008) Melting of DNA double strand after binding to geroprotective tetrapeptide